NAFLD/NASH in patients with type 2 diabetes and related treatment options

Journal of Endocrinological Investigation

Volumn 41, Issue 5, 2018, Pages 509-521

  Radaelli, M G ^a   Martucci, F ^a   Perra, S ^a   Accornero, S ^a   Castoldi, G ^b   Lattuada, G ^a   Manzoni, G ^a   Perseghin, G ^a,b  

^a Policlinico di Monza   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Cirrhosis; Fatty liver index (FLI); Fibrosis; Hepatocellular ballooning; Hepatocellular carcinoma; NAFLD score

Indexed keywords

ALPHA TOCOPHEROL; ELAFIBRANOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; OBETICHOLIC ACID; PIOGLITAZONE;

ACUTE LIVER FAILURE; ATRIAL FIBRILLATION; BARIATRIC SURGERY; BILE DUCT CARCINOMA; BODY WEIGHT LOSS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE ACTIVITY; ENDOTHELIAL DYSFUNCTION; ENERGY METABOLISM; EXERCISE; HEART FUNCTION; HEPATITIS C; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PANCREAS ISLET BETA CELL; PATHOGENESIS; PERIPHERAL NEUROPATHY; REVIEW; VALVULAR HEART DISEASE; CARDIOVASCULAR DISEASE; COMPLICATION; PATHOPHYSIOLOGY; PROGNOSIS;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS;

EID: 85035775262     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-017-0799-3     Document Type: Review

References (122)

1. Trombetta M, Spiazzi G, Zoppini G et al (2005) Type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther 22(Suppl 2):24–27
2. De Marco R, Locatelli F, Zoppini G et al (1999) Cause-specific mortality in type 2 diabetes. The Verona diabetes study. Diabetes Care 22:756–761
3. Der Diabetes Mellitus (1906) In: Naunyn B (ed) Nothnagels Handbuch. Wien: A. Holder
4. Perseghin G, Mazzaferro V, Sereni LP et al (2000) Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation. Hepatology 31:694–703
5. Megyesi C, Samols E, Marks V (1967) Glucose tolerance and diabetes in chronic liver disease. Lancet 2:1051–1056
6. Conn HO, Schreiber W, Elkington SG et al (1969) Cirrhosis and diabetes. Increased incidence of diabetes in patients with Laennec’s cirrhosis. I. Am J Dig Dis 14:837–852
7. Conn HO, Schreiber W, Elkington SG (1971) Cirrhosis and diabetes. Association of impaired glucose tolerance with portal-systemic shunting in Laennec’s cirrhosis. Am J Dig Dis 16:227–239
8. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM et al (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 107:811–826
9. EASL-EASD-EASO (2016) Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59:1121–1240
10. Marchesini G, Brizi M, Bianchi G et al (2001) Nonalcoholic fatty liver disease; a feature of the metabolic syndrome. Diabetes 50:1844–1850
11. Pietilainen KH, Rissanen A, Kaprio J et al (2005) Acquired obesity is associated with increased liver fat, intra-abdominal fat, and insulin resistance in young adult monozygotic twins. Am J Physiol Endocrinol Metab 288:E768–E774
12. Rocha ALL, Faria LC, Guimarães TCM, Moreira GV, Cândido AL et al (2017) Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis. J Endocrinol Investig. https://doi.org/10.1007/s40618-017-0708-9
13. Lee SH, Yun JM, Kim SH, Seo YG, Min H et al (2016) Association between bone mineral density and nonalcoholic fatty liver disease in Korean adults. J Endocrinol Investig 39:1329–1336
14. Petersen KF, Dufour S, Befroy D et al (2005) Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54:603–608
15. Ryysy L, Häkkinen A-M, Goto T et al (2000) Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49:749–758
16. Hwang J-H, Stein DT, Barzilai N et al (2007) Increased intrahepatic is associated with peripheral insulin resistance: in vivo MR imaging and spectroscopy. Am J Physiol Endocrinol Metab 293:E1663–E1669
17. Marchesini G, Brizi M, Morselli-Labate AM et al (1999) Association of non-alcoholic fatty liver disease with insulin resistance. Am J Med 107:450–455
18. Gastaldelli A, Cusi K, Pettiti M et al (2007) Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 133:496–506
19. Stefan N, Kantartzis K, Machann J et al (2008) Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 68:1609–1616
20. Perseghin G, Bonfanti R, Magni S et al (2006) Insulin resistance and whole body energy homeostasis in obese adolescents with fatty liver disease. Am J Physiol Endocrinol Metab 291:E697–E703
21. Petersen KF, Arioglu Oral E, Dufour S et al (2002) Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Investig 109:1345–1350
22. Perseghin G, Caumo A, Lattuada G et al (2009) Elevated fasting plasma C-peptide occurs in non-diabetic individuals with fatty liver irrespectively of insulin resistance. Diabet Med 26:847–854
23. Bedogni G, Gastaldelli A, Tiribelli C, Agosti F, De Col A et al (2014) Relationship between glucose metabolism and non-alcoholic fatty liver disease severity in morbidly obese women. J Endocrinol Investig 37:739–744
24. Kotronen A, Vehkavaara S, Seppälä-Lindroos A et al (2007) Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab 293:E1709–E1715
25. Kotronen A, Juurinen L, Tiikkainen M et al (2008) Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology 135:122–130
26. Battezzati A, Terruzzi I, Perseghin G et al (1995) Defective insulin action on protein and glucose metabolism during chronic hyperinsulinemia in subjects with benign insulinoma. Diabetes 44:837–844
27. Petrides AS, Stanley T, Matthews DE et al (1998) Insulin resistance in cirrhosis: prolonged reduction of hyperinsulinemia normalizes insulin sensitivity. Hepatology 28:141–149
28. Westerbacka J, Kolak M, Kiviluoto T et al (2007) Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes 56:2759–2765
29. Tripathy D, Mohanty P, Dhindsa S et al (2003) Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 52:2882–2887
30. Perseghin G, Petersen KF, Shulman GI (2003) Cellular mechanisms of insulin resistance; potential links with inflammation. Int J Obes 27:S6–S11
31. André P, Balkau B, Born C et al (2005) Hepatic markers and development of type 2 diabetes in middle aged men and women: a three-year follow-up study. The D.E.S.I.R. Study. [Data from an Epidemiological Study on the Insulin Resistance syndrome). Diabetes Metab 31:542–550
32. Fraser A, Thinggaard M, Christensen K, Lawlor DA (2009) Alanine aminotransferase, gamma-glutamyltransferase (GGT) and all cause mortality: results from a population-based Danish twins study alanine aminotransferase, GGT and mortality in elderly twins. Liver Int 29:1494–1499
33. Sattar N, Scherbakova O, Ford I et al (2004) Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 53:2855–2860
34. Shlomai A, Kariv R, Leshno M et al (2010) Large-scale population analysis reveals an extremely low threshold for “non-healthy” alanine aminotransferase that predicts diabetes mellitus. J Gastroenterol Hepatol 25:1687–1691
35. Kim CH, Park JY, Lee KU et al (2008) Fatty liver is an independent risk factor for the development of type 2 diabetes in Korean adults. Diabet Med 25:476–781
36. Fan JG, Li F, Cai XB et al (2007) Effects of non alcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 22:1086–1091
37. Shibata M, Kihara Y, Taguchi M et al (2007) Non-alcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 30:2940–2944
38. Bedogni G, Bellentani S, Miglioli L et al (2006) The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6:33
39. Balkau B, Lange C, Vol S, Fumeron F, Bonnet F, For Group Study D.E.S.I.R. (2010) Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol 10:56
40. Targher G, Chonchol MB, Byrne CD (2014) CKD and nonalcoholic fatty liver disease. Am J Kidney Dis 64:638–652
41. Musso G, Gambino R, Tabibian JH et al (2014) Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 11:e1001680
42. Mantovani A, Rigolon R, Mingolla L et al (2017) Nonalcoholic fatty liver disease is associated with an increased prevalence of distal symmetric polyneuropathy in adult patients with type 1 diabetes. J Diabetes Complicat 31:1021–1026
43. Liccardo D, Mosca A, Petroni S et al (2015) The association between retinal microvascular changes, metabolic risk factors, and liver histology in pediatric patients with non-alcoholic fatty liver disease (NAFLD). J Gastroenterol 50:903–912
44. Perseghin G (2010) The role of non-alcoholic fatty liver disease in cardiovascular disease. Dig Dis 28:210–213
45. Targher G, Day CP, Bonora E (2010) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363:1341–1350
46. Villanova N, Moscatiello S, Ramilli S et al (2005) Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42:473–480
47. Lautamaki R, Borra R, Iozzo P et al (2006) Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 291:E282–E290
48. Assy N, Djibre A, Farah R et al (2010) Presence of coronary plaques in patients with non-alcoholic fatty liver disease. Radiology 254:393–400
49. Perseghin G, Lattuada G, De Cobelli F et al (2008) Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 47:51–58
50. Bonapace S, Perseghin G, Molon G et al (2012) Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 35:389–395
51. Mantovani A, Pernigo M, Bergamini C et al (2015) nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. PLoS One 10:e0135329
52. Alonso A, Misialek JR, Amiin MA et al (2014) Circulating levels of liver enzymes and incidence of atrial fibrillation: the atherosclerosis risk in communities cohort. Heart 100:1511–1516
53. Markus MR, Meffert PJ, Baumeister SE, Lieb W, Siewert U et al (2016) Association between hepatic steatosis and serum liver enzyme levels with atrial fibrillation in the general population: the Study of Health in Pomerania (SHIP). Atherosclerosis 245:123–131
54. Targher G, Valbusa F, Bonapace S et al (2013) Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One 8:e57183
55. Targher G, Mantovani A, Pichiri I et al (2013) Nonalcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin Sci (Lond) 125:301–309
56. Mantovani A, Rigolon R, Pichiri I et al (2017) Nonalcoholic fatty liver disease is associated with an increased risk of heart block in hospitalized patients with type 2 diabetes mellitus. PLoS One 12:e0185459
57. Mantovani A, Pernigo M, Bergamini C et al (2015) Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism 64:879–887
58. Wannamethee SG, Lennon L, Shaper AG (2008) The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes. Atherosclerosis 201:168–175
59. Hamaguchi M, Kojima T, Takeda N et al (2007) Non-alcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 13:1579–1584
60. Targher G, Bertolini L, Poli F et al (2005) Non-alcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54:3541–3546
61. Targher G, Bertolini L, Rodella S et al (2007) Non-alcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 30:2119–2121
62. Haring R, Wallaschofski H, Nauck M et al (2009) Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl-transpeptidase levels. Hepatology 50:1403–1411
63. Calori G, Lattuada G, Ragogna F et al (2011) Fatty liver index (FLI) and mortality: the Cremona Study in the 15th year of follow up. Hepatology 54:145–152
64. McKimmie RL, Daniel KR, Carr J et al (2008) Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the diabetes heart study. Am J Gastroenterol 103:3029–3035
65. Petit JM, Guiu B, Terriat B et al (2009) Non-alcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients. J Clin Endocrinol Metab 94:4103–4106
66. Targher G, Bertolini L, Padovani R, Poli F, Scala L et al (2006) Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients. J Endocrinol Investig 29:55–60
67. Day CP, James OF (1998) Steatohepatitis: a tale of two “hits”? Gastroenterology 114:842–845
68. Tilg H, Moschen AR (2010) Evolution of inflammation in non-alcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52:1836–1846
69. Labruna G, Pasanisi F, Nardelli C, Tarantino G, Vitale DF et al (2009) UCP1-3826 AG + GG genotypes, adiponectin, and leptin/adiponectin ratio in severe obesity. J Endocrinol Investig 32:525–529
70. Loria P, Lonardo A, Anania F (2013) Liver and diabetes. A vicious circle. Hepatol Res 43:51–64
71. Starley BQ, Calcagno CJ, Harrison SA (2010) Non-alcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51:1820–1832
72. Peyrou M, Bourgoin L, Foti M (2010) PTEN in liver diseases and cancer. World J Gastroenterol 16:4627–4633
73. Nkontchou G, Cosson E, Aout M et al (2011) Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 96:2601–2608
74. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA (2012) Association of Thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 55:1462–1472
75. Wanless IR, Lentz JS (1990) Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12:1106–1110
76. Adams LA, Lymp JF, St Sauver J et al (2005) The natural history of nonalcoholic fatty liver disease: a population based cohort study. Gastroenterology 129:113–121
77. Adams LA, Harmsen S, St Sauver JL et al (2010) Non-alcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 105:1567–1573
78. The US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: OPTN/SRTR annual report: table 9.4a: transplant recipient characteristics, 1995 to 2004: recipients of deceased donor livers [Internet), Ann Arbor, MI. Available from http://www.optn.org/AR2005/904a_rec-dgn_li.htm. Accessed 2 May 2005
79. Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829–841
80. El-Serag HB, Tran T, Everhart JE et al (2004) Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126:460–468
81. Welzel TM, Graubard BI, Zeuzem S et al (2011) Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEERMedicare database. Hepatology 54:463–471
82. Paradis V, Zalinski S, Chelbi E et al (2009) Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 49:851–859
83. Ertle J, Dechêne A, Sowa JP et al (2011) Non-alcoholic fatty liver disease progresses to HCC in the absence of apparent cirrhosis. Int J Cancer 128:2436–2443
84. Simo R, Hernandez C, Genesca J, Jardi R, Mesa J (1996) High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 19:998–1000
85. Ozyilkan E, Arslan M (1996) Increased prevalence of diabetes mellitus in patients with chronic hepatitis C virus infection. Am J Gastroenterol 91:1480–1481
86. Kawaguchi T, Yoshida T, Harada M et al (2004) Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through upregulation of suppressor of cytokine signalling 3. Am J Pathol 165:1499–1508
87. Rubbia-Brandt L, Leandro G, Spahr L et al (2001) Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology 39:119–124
88. El-Serag HB, Everhart JE (2002) Diabetes increases the risk of acute hepatic failure. Gastroenterology 122:1822–1828
89. Chan KA, Truman A, Gurwitz JH et al (2003) A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycaemic agents. Arch Intern Med 163:728–734
90. Zimmerman HJ (1991) Drug-induced liver disease. In: Zimmerman HJ (ed) Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver, 2nd edn. Lippincott Williams and Williams, Philadelphia, pp 427–456
91. Byrne CD, Targher G (2016) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate? Diabetologia 59:1141–1144
92. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley K, Chalasani N, Lavine J, Ratziu V, McCullough A (2011) Endpoints and clinical trial design for non-alcoholic steatohepatitis. Hepatology 54(1):344–353
93. Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L (2015) American Association for the Study of Liver Diseases; United States Food and Drug Administration Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-US Food and Drug Administration Joint Workshop. Hepatology 61(4):1392–1405
94. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ et al (2005) Non-alcoholic steatohepatitis clinical research network. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology 41(6):1313–1321
95. Thoma C, Day CP, Trenell MI (2012) Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 56:255–266
96. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B et al (2015) Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149:367–378
97. Vilar-Gomez E, Yasells-Garcia A, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A et al (2016) Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. Hepatology 63:1875–1887
98. Kastorini CM, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB (2011) The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol 57:1299–1313
99. Boden G (2009) High- or low-carbohydrate diets: which is better for weight loss, insulin resistance, and fatty livers? Gastroenterology 136:1490–1492
100. Perseghin G, Lattuada G, De Cobelli F et al (2007) Habitual physical activity is associated with the intra-hepatic fat content in humans. Diabetes Care 30:683–688
101. Keating SE, Hackett DA, Parker HM, O’Connor HT, Gerofi JA et al (2015) Effect of aerobic exercise training dose on liver fat and visceral adiposity. J Hepatol 63:174–182
102. Hashida R, Kawaguchi T, Bekki M, Omoto M, Matsuse H et al (2017) Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review. J Hepatol 66:142–152
103. Belfort R, Harrison SA, Brown K et al (2006) A placebo-controlled trial of Pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355:2297–2307
104. Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J et al (2016) Long-term Pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med 165:305–315
105. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD et al (2008) Randomized, placebo-controlled trial of Pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135:1176–1184
106. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM et al (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362:1675–1685
107. Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M et al (2010) LIDO Study Group. Long-term efficacy of rosiglitazone in non-alcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51:445–453
108. Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M (2010) Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis 28:220–224
109. Karpen SJ (2013) Do therapeutic bile acids hit the sweet spot of glucose metabolism in NAFLD? Gastroenterology 145:508–510
110. Cipriani S, Mencarelli A, Palladino G, Fiorucci S (2010) FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 51:771–784
111. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF et al (2015) Farnesoid X nuclear receptor ligand Obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385:956–965
112. Gupta NA, Mells J, Dunham RM et al (2010) Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 51:1584–1592
113. Ben-Shlomo S, Zvibel I, Shnell M et al (2011) Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol 54:1214–1223
114. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387:679–690
115. Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K et al (2012) Bariatric surgery and long-term cardiovascular events. JAMA 307:56–65
116. Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H et al (2015) Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 149:379–388
117. Staels B, Rubenstrunk A, Noel B et al (2013) Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 58:1941–1952
118. Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P et al (2016) GOLDEN-505 Investigator Study Group. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of non-alcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150:1147–1159
119. Ito D, Shimizu S, Inoue K, Saito D, Yanagisawa M et al (2017) Comparison of Ipragliflozin and Pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care. https://doi.org/10.2337/dc17-0518 (Epub ahead of print)
120. Shibuya T, Fushimi N, Kawai M, Yoshida Y, Hachiya H et al (2017) Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study. Diabetes Obes Metab. https://doi.org/10.1111/dom.13061
121. Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D et al (2015) High prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab 100:2231–2238
122. Bellentani S, Dalle Grave R, Suppini A, Marchesini G, The Fatty Liver Italian Network [FLIN] (2008) Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology 47:746–754